Scientific Publications (Open Access) – Treatment Action Group

Missing voices: building women living with HIV’s meaningful engagement in HIV clinical and cure research – Susan C. S. Chong et al, Culture, Health & Sexuality, September 27, 2024
People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis – Marc Antoine Jean Juste et al, Pathogens and Immunity, September 23, 2024
HIV reservoir and premature aging: risk factors for aging-associated illness in adolescents and young adults with perinatally acquired HIV – Maria Raffaella Petrara et al, PLoS Pathogens, September 23, 2024
The impact of sex on HIV immunopathogenesis and therapeutic interventions – Erin Mihealsick et al, Journal of Clinical Investigation, September 17, 2024
Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study – Luling Wu, Signal Transduction and Targeted Therapy, September 9, 2024
Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells – Asier Sáez-Cirión et al, Nature Medicine, September 2, 2024
Avancing towards HIV-1 remission: Insights and innovations in stem cell therapies – Aditi Chatterjee et al, Archives of Stem Cell and Therapy, September 2024
The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis – Ming Jie Lee et al, Journal of the International AIDS Society, August 18, 2024
Impact of antiretroviral therapy during primary HIV infection on T-cell immunity after treatment interruption – Timothy Tipoe et al, European Journal of Immunology, August 13, 2024
Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion – Tin Phan et al, PLoS Pathogens, July 29, 2024
Spatial technologies to evaluate the HIV-1 reservoir and its microenvironment in the lymph node – Fatima Zaman et al, mBio, July 26, 2024
Make gene therapies more available by manufacturing them in lower-income nations – Evelyn Mwesigwa Harlow and Jennifer E. Adair, Nature, July 17, 2024
Exceptional, naturally occurring HIV-1 control: Insight into a functional cure – María Salgado et al, Med, July 15, 2024
Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size – Maria Reyes Jimenez-Leon et al, JCI Insight, July 9, 2024
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial – Jasmini Alagaratnam et al, Journal of Virus Eradication, June 13, 2024
Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiation – Jaimy Joy et al, Journal of Clinical Investigation, June 4, 2024
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study – María Salgado et al, Lancet HIV, June 2024
Delivering CRISPR to the HIV-1 reservoirs – Theodore E. Gurrol et al, Frontiers in Microbiology, May 14, 2024
The translational gap for gene therapies in low- and middle-income countries – Kevin W. Doxzen et al, Science Translational Medicine, May 8, 2024
Nothing about us without us: Advocacy and engagement in genetic medicine – Olabimpe Olayiwola et al, Science Translational Medicine, May 8, 2024
Pediatric immunotherapy and HIV control – Tehillah T. Chinunga et al, Current Opinion in HIV and AIDS, May 2, 2024
Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy Indicating A Lack Of Ongoing Viral Replication – Sook-Kyung Lee et al, Open Forum Infectious Diseases, April 17, 2024
Targeting Viral Transcription for HIV Cure Strategies – Jon Izquierdo-Pujol et al, Microorganisms, April 8, 2024
Beyond community engagement: perspectives on the meaningful involvement of people with HIV and affected communities (MIPA) in HIV cure research in The Netherlands – Tamika A. Marcos et al, HIV Research & Clinical Practice, April 5, 2024
Evaluation of HIV-1 DNA levels among adolescents living with perinatally acquired HIV-1 in Yaounde, Cameroon: A contribution to paediatric HIV cure research in Sub-Saharan Africa – Aude Christelle Ka’e et al, Journal of Virus Eradication, March 30, 2024
Factors associated with unquantifiable total HIV-1 DNA in peripheral blood in persons living with HIV: An observational study – Aurélie Ram et al, Journal of Virus Eradication, March 28, 2024
Quantitative and Qualitative Distinctions between HIV-1 and SIV Reservoirs: Implications for HIV-1 Cure-Related Studies – Joseph C. Mudd, Viruses, March 27, 2024
Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1 – Niklas Beschorner et al, PLoS One, March 8, 2024
Advancing HIV cure research in low- and middle-income countries requires empowerment of the next generation of scientists – Roger Tatoud et al, Journal of Virus Eradication, March 6, 2024
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a – Marie Armani-Tourret et al, Cell, February 16 ,2024
HIV cure: The daunting scale of the problem – Janet D. Siliciano and Robert F. Siliciano, Science, February 15 ,2024
Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States – Karine Dubé et al, HIV Research & Clinical Practice, January 29, 2024
Quantifying the HIV reservoir with dilution assays and deep viral sequencing – Sarah C. Lotspeich, Biometrics, January 29, 2024
CD4+ T cells with latent HIV-1 have reduced proliferative responses to T cell receptor stimulation – Joshua T. Kufera et al, Journal of Experimental Medicine, January 25, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy – Cynthia Gay et al, Open Forum Infectious Diseases, January 11, 2024
Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir – Marion Pardons et al, Nature Communications, December 18, 2023
Persistence of intact HIV-1 proviruses in the brain during antiretroviral therapy – Weiwei Sun et al, eLife, November 8, 2023
A follow-up study: 6-year cART-free virologic control of rhesus macaques after PD-1-based DNA vaccination against pathogenic SHIVSF162P3CN challenge – Xiaoen He et al, Microbiology Spectrum, November 3, 2023
The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency – Hannah S. Sperber et al, Cell Reports, October 31, 2023
Host immunity associated with spontaneous suppression of viremia in therapy-naïve young rhesus macaques following neonatal SHIV infection – Tyler D. Evangelous et al, Journal of Virology, October 24, 2023
People with HIV at the end of life and their next-of-kin/loved ones are willing to participate in interventional HIV cure-related research – Samuel O. Ndukwe et al, AIDS, October 18, 2023
Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States – Andrea Bilger et al, HIV Research and Clinical Practice, October 14, 2023
An active HIV reservoir during ART is associated with maintenance of HIV-specific CD8+ T cell magnitude and short-lived differentiation status – Hiroshi Takata et al, Cell Host & Microbe, September 13, 2023
Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells – Mathieu Dubé et al, Cell Host & Microbe, September 13, 2023
An individual community member’s perspective on HIV cure-related research – Thomas J. Villa, HIV Research and Clinical Practice, August 24, 2023
‘With this study, we have hope that something is coming’: community members’ perceptions of HIV cure-related research in Durban, South Africa – a qualitative focus group study – Karine Dubé et al, HIV Research and Clinical Practice, July 29, 2023
Peripheral blood biomarkers predict viral rebound following antiretroviral therapy discontinuation in SIV-infected, early ART-treated rhesus macaques – Malika Aid et al, Cell Reports Medicine, July 18, 2023
The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy – Natalie F. McMyn et al, Journal of Clinical Investigation, July 18, 2023
Impact of misclassified defective proviruses on HIV reservoir measurements – Daniel B. Reeves et al, Nature Communications, July 13, 2023
Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections – Wanwisa Promsote et al, Nature Communications, June 22, 2023
Recent advances in CD8+ T cell-based immune therapies for HIV cure – Valentina Restrepo Arenas, María T. Rugeles, Federico Perdomo-Celis and Natalia Taborda, Heliyon, June 20, 2023
Community engagement group model in basic and biomedical research: lessons learned from the BEAT-HIV Delaney Collaboratory towards an HIV-1 cure – Karine Dubé et al, Research Involvement and Engagement, June 8, 2023
Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United States – Karine Dubé et al, Journal of Virus Eradication, June 5, 2023
Healthcare Provider Perspectives on HIV Cure Research in Ghana – Helena Lamptey et al, AIDS Research and Treatment, May 31, 2023
Reduced CCR5 expression among Uganda HIV controllers – Brian Nyiro et al, Retrovirology, May 25, 2023
A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life – Karine Dubé et al, Pathogens and Immunity, May 24, 2023
Multi-ancestry sex-stratified genomic associations with HIV viral load and controller status from the ICGH – Candelaria Vergara et al, JCI Insight, April 25, 2023
Targeted plasma proteomics identifies MICA and IL1R1 proteins associated with HIV-1 reservoir size – Marc J.T. Blaauw et al, iScience, March 22, 2023
Opportunities for CAR-T Cell Immunotherapy in HIV Cure – Gerard Campos-Gonzalez et al, Viruses, March 19, 2023
HIV-1 remission and possible cure in a woman after haplo-cord blood transplant – Jingmei Hsu et al, Cell, March 16, 2023
The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy – Henrieke A.B. Prins et al, Science Advances, March 17, 2023
Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomes – Caroline Dufour et al, Nature Communications February 27, 2023
In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation – Björn-Erik Ole Jensen et al, Nature Medicine, February 20, 2023
HIV persistence: silence or resistance? – Alexander O. Pasternak and Ben Berkhout, Current Opinion in Virology, February 17, 2023
In-Depth Characterization of Full-Length Archived Viral Genomes after Nine Years of Posttreatment HIV Control – Pauline Trémeaux et al, Microbiology Spectrum, January 24, 2023
A CRISPR-Cas Cure for HIV/AIDS – Mouraya Hussei et al, International Journal of Molecular Sciences, January 13, 2023
Phenotypic signatures of immune selection in HIV-1 reservoir cells – Weiwei Sun et al, Nature, January 4, 2023
HIV silencing and cell survival signatures in infected T cell reservoirs – Iain C. Clark et al, Nature, January 4, 2023
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy – Xiaodong Lian et al, Cell Host & Microbe, December 28, 2022
Abstracts of the Tenth International Workshop on HIV Persistence during Therapy December 13 to 16, 2022 Miami, Florida, USA – Journal of Virus Eradication, December 2022
HIV reservoir: antiviral immune responses and immune interventions for curing HIV infection – Shuang Li et al, Chinese Medical Journal, November 20, 2022
HIV cure: an acceptability scientific agenda – Evelyn Y Bonney, Helena Lamptey and George B Kyei, Current Opinion in HIV and AIDS, November 9, 2022
HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy – Aniqa Shahid et al, PLoS Pathogens, November 4, 2022
Prime, shock and kill: BCL-2 inhibition for HIV cure – Aswath P. Chandrasekar and Andrew D. Badley, Frontiers in Immunology, October 20, 2022
MiRNA-103 downmodulates CCR5 expression reducing HIV-1 entry and impacting latency establishment in CD4+ T cells – Nicolas Bellini et al, iScience, September 27, 2022
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8 + T cells – Hiroshi Takata et al, EBioMedicine, September 8, 2022
Distinct gene expression by expanded clones of quiescent memory CD4 + T cells harboring intact latent HIV-1 proviruses – Georg H.J. Weymar et al, Cell Reports, September 6, 2022
“In diversity there is beauty and there is strength.” -Dr. Maya Angelou A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-Related Research – Danielle M. Campbell et al, Journal of AIDS, September 2, 2022
Bispecific antibody-derived molecules to target persistent HIV infection – Jeffrey L Nordstrom, Guido Ferrari and David M Margolis, Journal of Virus Eradication, August 28, 2022
The role of latency reversal in HIV cure strategies – Kiho Tanaka et al, Journal of Medical Primatology, August 27, 2022
Combination strategies to durably suppress HIV-1: Soluble T cell receptors – Zoë Wallace, Praveen K. Singh and Lucy Dorrell, Journal of Virus Eradication, August 24, 2022
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells – Eva M. Stevenson et al, Nature Communications, August 19, 2022
Participant experiences using novel home-based blood collection device for viral load testing in the HIV cure trials with analytical treatment interruptions – Karine Dubé et al, HIV Research & Clinical Practice, August 13, 2022
An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection – Mathias Lichterfeld, Ce Gao and Xu G. Yu, Trends in Immunology, August 1, 2022
Intact HIV proviruses persist in the brain despite viral suppression with ART – Catherine R. Cochrane et al, Annals of Neurology, July 22, 2022
Immune correlates of HIV-1 reservoir cell decline in early-treated infants – Ciputra Adijaya Hartana et al, Cell Reports, July 19, 2022
Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure – Stella J. Berendam et al, Frontiers in Immunology, July 13, 2022
“It comes altogether as one:” perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States – Danielle M. Campbell et al, BMC Public Health, July 9, 2022
HIV cure strategies: which ones are appropriate for Africa? – Christopher Zaab-Yen Abana et al, Cellular and Molecular Life Sciences, July 6, 2022
Genotypic and Phenotypic Diversity of the Replication-Competent HIV Reservoir in Treated Patients – Alexandre Nicolas et al, Microbiology Spectrum, June 30, 2022
Lessons learned from the Last Gift study: ethical and practical challenges faced while conducting HIV cure-related research at the end of life – John Kanazawa et al, Journal of Medical Ethics, June 22, 2022
Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir – Madhu C.Choudhary, Joshua C.Cyktor and Sharon A. Riddler, Journal of Virus Eradication, June 18, 2022
Current strategies to induce selective killing of HIV-1-infected cells – Grant R. Campbell and Stephen A. Spector, Journal of Leukocyte Biology, June 16, 2022
Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques – Victoria E. K. Walker-Sperling et al, Nature Communications, June 16, 2022
Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection – Pienvan Paassen et al, Journal of Virus Eradication, June 15, 2022
Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches – Jose A. Moran, Shireen R. Turner and Matthew D. Marsden, Frontiers in Immunology, May 25, 2022
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques – John D. Ventura et al, npj Vaccines, 18 May 2022
Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era – Vinicius A. Vieira et al, Frontiers in Immunology, May 11, 2022
Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy – Jarrod York et al, Frontiers in Immunology, April 29, 2022
Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption – Basiel Cole et al, Cell Reports, April 26, 2022
Prolonged viral suppression with anti-HIV-1 antibody therapy – Christian Gaebler, Nature, April 13, 2022
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers – Luis M. Molinos-Albert et al, Nature Communications, April 11, 2022
Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States – Karine Dubé et al, BMC Medical Ethics, April 9, 2022
Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size – Thomas A. Rasmussen et al, Clinical Infectious Diseases, April 9, 2022
Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control – Federico Perdomo-Celis et al, Journal of Clinical Investigation, April 5, 2022
The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV – Ming Jie Lee et al, Trials, April 5, 2022
“We are looking at the future right now”: community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States – Karine Dubé et al, HIV Research & Clinical Practice, March 29, 2022
Paradoxically greater persistence of HIV RNA+ cells in lymphoid tissue when ART is initiated in the earliest stage of infection – Eugène Kroon et al, The Journal of Infectious Diseases, March 11, 2022
Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy – Justin Harper et al, Journal of Clinical Investigation, March 1, 2022
Plasma-Derived HIV-1 Virions Contain Considerable Levels of Defective Genomes – Katie Fisher et al, Journal of Virology, February 24, 2022
Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19 – Merle Henderson et al, JIAS, February 9, 2022
The HIV-1 proviral landscape reveals Nef contributes to HIV-1 persistence in effector memory CD4+ T-cells – Gabriel Duette et al, Journal of Clinical Investigation, February 8, 2022
CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection – Mary S. Pampusch et al, PLoS Pathogens, February 7, 2022
Bringing social context into global biomedical HIV cure-related research: An urgent call to action – Annie Miall et al, Journal of Virus Eradication, February 4, 2022
Immune checkpoint blockade in HIV – Celine Gubser et al, EBioMedicine, February 2, 2022
Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC – C. N. Kibirige et al, Scientific Reports, January 28, 2022
Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry – Mathieu Claireaux et al, Nature Communications, January 26, 2022
Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda – Samira Joussef-Piña et al, Retrovirology, January 15, 2022
Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses – Kevin B. Einkauf et al, Cell, January 12, 2022
Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States – John Kanazawa et al, BMC Medical Ethics, January 11, 2022
Latency reversal plus natural killer cells diminish HIV reservoir in vivo – Jocelyn T. Kim et al, Nature Communications, January 10, 2022
Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound – Penny Zacharopoulou et al, Scientific Reports, January 10, 2022
Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers – Anabela C. P. Picton et al, Frontiers in Immunology, December 20, 2021
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 – Steven G. Deeks et al, Nature Medicine, December 1, 2021
Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy – Cristina Gálvez et al, mBio, November 30, 2021
Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo – Nathan Cummins et al, EClinicalMedicine, November 29, 2021
Fighting HIV-1 Persistence: At the Crossroads of “Shoc-K and B-Lock” – Chiara Acchioni et al, Pathogens, November 20, 2021
Are HIV-1-Specific Antibody Levels Potentially Useful Laboratory Markers to Estimate HIV Reservoir Size? A Review – Silvere D. Zaongo et al, Frontiers in Immunology, November 11, 2021
Two distinct mechanisms leading to loss of virological control in the rare group of antiretroviral therapy-naïve, transiently aviraemic children living with HIV – Vinicius A. Vieira et al, Journal of Virology, November 10, 2021
T-cell receptor-specific immunotherapeutics drive selective in vivo HIV and CMV-specific T-cell expansion in humanized mice – Mengyan Li et al, Journal of Clinical Investigation, October 21, 2021
Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence – Amy S. Huang et al, Journal of Experimental Medicine, October 12,
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial – Kathryn E. Stephenson et al, Nature Medicine, October 7, 2021
Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial – Helen Payne, AIDS Research and Therapy, September 29, 2021
Targeting and Understanding HIV Latency: The CRISPR System against the Provirus – Gloria Magro, Arianna Calistri and Cristina Parolin, Pathogens, September 28, 2021
Exosome-mediated stable epigenetic repression of HIV-1 – Surya Shrivastava et al, Nature Communications, September 20, 2021
Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI) – Jennifer E. Adair et al, Gene Therapy, September 8, 2021
Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART – Kelsie Brooks et al, Frontiers in Microbiology, August 19, 2021
Broadly neutralizing antibody-derived CAR-T cells reduce viral reservoir in HIV-1-infected individuals – Bingfeng Liu et al, Journal of Clinical Investigation, August 10, 2021
Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study – Rossana Scutari et al, Viruses, July 19, 2021
Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure – Grant R. Campbell and Stephen A. Spector, Cells, July 16, 2021
Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? – Denise C. Hsu, John W. Mellors and Sandhya Vasan, Frontiers in Immunology, July 12, 2021
Ethics of HIV cure research: an unfinished agenda – Karine Dubé et al, BMC Medical Ethics, June 30, 2021
Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV – Leila B. Giron et al, Nature Communications, June 29, 2021
Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir – Taina T. Immonen et al, PLoS Pathogens, June 18, 2021
In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia – Basiel Cole et al, Nature Communications, June 17, 2021
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium – C. Rokx et al, Journal of Virus Eradication, May 23, 2021
Comparison of methods to quantify inducible HIV-1 outgrowth – P. Nathan Enick et al, Journal of Virus Eradication, May 17, 2021
Attitudes and perceptions of next-of-kin/loved ones toward end-of-life HIV cure-related research: A qualitative focus group study in Southern California – Sogol S. Javadi et al, PLoS One, May 7, 2021
A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir – Claire N. Levy et al, Cell Reports Medicine, April 12, 2021
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure? – Ignasi Esteban et al, Viruses, March 18, 2021
CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication – Pablo Tebas et al, Journal of Clinical Investigation, February 11, 2021
Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings – Jillian SY.Lau et al, Journal of Virus Eradication, February 7, 2021
Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART – Charline Bacchus-Souffan et al, PLoS Pathogens, January 19, 2021
Latency Reversal 2.0: Giving the Immune System a Seat at the Table – Vidisha Singh, Amir Dashti, Maud Mavigner and Ann Chahroudi, Current HIV/AIDS Reports, January 12, 2021
HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA) – Natalie N. Kinloch et al, Nature Communications, January 8, 2021
Sequence evaluation and comparative analysis of novel assays for intact proviral HIV-1 DNA – Christian Gaebler et al, Journal of Virology, December 23, 2020
Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection – Uruena A, Cassetti et al, Open Forum Infectious Diseases, December 15, 2020
Re-examining the HIV ‘functional cure’ oxymoron: Time for precise terminology? – Karine Dubé et al, Journal of Virus Eradication, November 2020
Persistence of an intact HIV reservoir in phenotypically naive T cells – Emmanuele Venanzi Rullo et al, JCI Insight, October 15, 2020
Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1 – Sharon A. Riddler et al, Clinical Infectious Diseases, October 12, 2020
Immunological approaches to HIV cure – Adam R. Ward, Talia M. Mota, Brad Jones, Seminars in Immunology, September 24, 2020
A landscape analysis of HIV cure-related clinical research in 2019 – Liz Barr and Richard Jefferys, Journal of Virus Eradication, September 2, 2020
How ‘elite controllers’ tame HIV without drugs – Jon Cohen, Science Magazine, August 26, 2020
HIV enters deep sleep in people who naturally control the virus – Nicolas Chomont, Nature, August 26, 2020
Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: A collaborative approach – Michael J. Paluso et al, Clinical Infectious Diseases, August 25, 2020
Block and Lock HIV Cure Strategies to Control the Latent Reservoir – Chantelle L. Ahlenstiel et al, Frontiers in Cellular and Infection Microbiology, August 14, 2020
Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART – Pierre Gantner et al, Nature Communications, August 14, 2020
Clearance of HIV infection by selective elimination of host cells capable of producing HIV – Min Li et al, Nature Communications, August 13, 2020
Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response – Lorna Leal et al, Vaccines, August 5, 2020
The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination – Nabila Seddiki et al, Vaccines, July 27, 2020
Sex differences in CMV Replication and HIV Persistence during Suppressive ART – Sara Gianella et al, Open Forum Infectious Diseases, July 11, 2020
An intriguing—but far from proven—HIV cure in the ‘São Paulo Patient’ – Jon Cohen, Science, July 7, 2020
Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation – Ping-Hsien Lee et al, Frontiers in Cellular and Infection Microbiology, July 7, 2020
Parallel but Connected: Nuances of Conducting Behavioral and Social Science Research Alongside Ethically Challenging HIV Remission Trials – Gail Henderson et al, Contemporary Clinical Trials Communications, June 16, 2020
Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among females in Rakai, Uganda – Jessica L. Prodger et al, JCI Insight, June 16, 2020
The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies – Janne Tegder Martinsen et al, Frontiers in Immunology, June 11, 2020
How Close Are We to a Cure for HIV? – Della Xu and David E. Koren, Contagion Live, June 11, 2020
HIV Cure Research Has Slowed, But Still Progresses – Laurie Saloman, Contagion Live, May 31, 2020
HIV Diversity Considerations in the Application of the Intact Proviral DNA Assay (IPDA) – Natalie N. Kinloch et al, bioRxiv, May 29, 2020
Novel Approaches Towards a Functional Cure of HIV/AIDS – Lucia Bailon Alvarez et al, Drugs, May 20, 2020
HIV-1 Proviral Transcription and Latency in the New Era – Ashutosh Shukla, Nora-Guadalupe P Ramirez and Iván D’Orso, Viruses, May 18, 2020
HIV-resistant and HIV-specific CAR-modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo – Colby R. Maldini et al, Molecular Therapy, May 14, 2020
Pattern Recognition Receptor Ligands as an Emerging Therapeutic Agent for Latent HIV-1 Infection – Shokichi Takahama and Takuya Yamamoto, Frontiers in Cellular and Infection Microbiology, May 8, 2020
Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10–13 December 2019, Miami, USA – Christina K. Psomas et al. Journal of Virus Eradication, April 30, 2020
Antigen-responsive CD4+ T Cell Clones Contribute to the HIV-1 Latent Reservoir – Pilar Mendoza et al, Journal of Experimental Medicine, April 20, 2020
Moving Beyond the Mousetrap: Current and Emerging Humanized Mouse and Rat Models for Investigating Prevention and Cure Strategies Against HIV Infection and Associated Pathologies – Yash Agarwal et al, Retrovirology, April 10, 2020
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies – Lillian B. Cohn, Nicolas Chomont and Steven G. Deeks, Cell Host & Microbe, April 8, 2020
Measuring the Success of HIV-1 Cure Strategies – Jordan Thomas et al, Frontiers in Cellular and Infection Microbiology, April 7, 2020
CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA – Caroline S Binda et al, Viruses, March 18, 2020
Experimental treatment of SIV-infected macaques via autograft of CCR5-disrupted hematopoietic stem and progenitor cells – Songlin Yu et al, Molecular Therapy: Methods & Clinical Development, March 13, 2020
Advances in Developing CAR T-Cell Therapy for HIV Cure – Jinxin Qi et al, Frontiers in Immunology, March 10, 2020
A cure for HIV: how would we know? – Jennifer Zerbato and Sharon R Lewin, Lancet HIV, March 10, 2020
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report – Ravindra Kumar Gupta, et al, Lancet HIV, March 10, 2020
Single-Cell Technologies Applied to HIV-1 Research: Reaching Maturity – Gérémy Sannier, Mathieu Dubé and Daniel E. Kaufmann, Frontiers in Microbiology, March 4, 2020
The significance and expectations of HIV cure research among people living with HIV in Australia – Jennifer Power et al, PLoS One, March 4, 2020
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on‐going viral transcription – Pieter Pannus et al, Journal of the International AIDS Society, February 27, 2020
Immune Surveillance of the HIV Reservoir: Mechanisms, Therapeutic Targeting and New Avenues for HIV Cure – Julia G. Prado and John Frater, Frontiers in Immunology, January 31, 2020
Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy – Roland Schwarzer, Andrea Gramatica and Warner C. Greene, Viruses, February 8, 2020
Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure – Concepcion Casado et al, Scientific Reports, February 5, 2020
Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption – Julie L. Mitchell et al, Journal of Clinical Investigation, February 4, 2020
Differences in the induced latent HIV reservoir in perinatal and adult infection – Adit Dhummakupt et al, JCI Insight, January 30, 2020
Emerging PCR-Based Techniques to Study HIV-1 Reservoir Persistence – Laurens Lambrechts et al, Viruses, January 28, 2020
Report from the 9th HIV Persistence During Therapy Workshop – Christina K. Psomas, NATAP, January 13, 2020
Block-And-Lock Strategies to Cure HIV Infection – Gerlinde Vansant, Anne Bruggemans, Julie Janssens and Zeger Debyser, Viruses, January 10, 2020
HIV persists throughout deep tissues with repopulation from multiple anatomical sources – Antoine Chaillon et al, Journal of Clinical Investigation, January 7, 2020
Advances Toward a Cure for HIV: Getting Beyond n=2 – Jonathan Li, Topics in Antiviral Medicine, December 2019/January 2020
Therapeutic HIV Vaccines and Broadly Neutralizing Antibodies – Magdalena E. Sobieszczyk, Topics in Antiviral Medicine, December 2019/January 2020
Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients – Csaba Fehér et al, Open Forum Infectious Diseases, November 4, 2019
A landscape analysis of HIV cure-related clinical trials and observational studies in 2018 – Liz Barr and Richard Jefferys, Journal of Virus Eradication, October 22, 2019
From early AIDS vaccine to HIV cure research with analytical treatment interruption trials: a study participant testimonial – William Freshwater, Journal of Virus Eradication, October 22, 2019
Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research – M. Paximadis et al, Journal of Virus Eradication, October 22, 2019
Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists – Amanda B. Macedo, Camille L. Novis and Alberto Bosque, Frontiers in Immunology, October 15, 2019
Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms – Jana L. Jacobs, Elias K. Halvas, Melissa A. Tosiano and John W. Mellors, Frontiers in Microbiology, October 15, 2019
Does B Cell Follicle Exclusion of CD8+ T Cells Make Lymph Nodes Sanctuaries of HIV Replication? – Sarah E. Beck, Rebecca T. Veenhuis and Joel N. Blankson, Frontiers in Immunology, October 9, 2019
Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV – Christina Gavegnano et al, Frontiers in Immunology, October 4, 2019
HIV Infected T Cells Can Proliferate in vivo Without Inducing Expression of the Integrated Provirus – Andrew Musick et al, Frontiers in Microbiology, October 1, 2019
CAR Talk: How Cancer-specific CAR T cells can instruct how to build CAR T cells to Cure HIV – James L Riley , Gloria B Kim and Kristen Hege, Frontiers in Immunology, September 27, 2019
The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like – Gilles Darcis, Ben Berkhout and Alexander O. Pasternak, Frontiers in Immunology, September 20, 2019
Seeing Is Believing: Nuclear Imaging of HIV Persistence – Timothy J. Henrich, Priscilla Y. Hsue and Henry VanBrocklin, Frontiers in Immunology, September 12, 2019
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology – Geetha Mylvaganam , Adrienne G. Yanez , Marcela Maus and Bruce D. Walker, Frontiers in Immunology, September 10, 2019
What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study – Marion Fiorentino et al, Journal of Virus Eradication, September 2019
Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research – Camilla Muccini et al, AIDS Research and Therapy, September 6, 2019
The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy – Gabriela De Nardi Sanches-da-Silva, Luiza Fonseca Sales Medeiros and Fabio Mitsuo Lima, International Journal of Genomics, August 21, 2019
Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues – Paul W. Denton, Ole S. Søgaard and Martin Tolstrup, Frontiers in Microbiology, August 21, 2019
Learning From the Exceptions: HIV Remission in Post-treatment Controllers – Behzad Etemad, Elmira Esmaeilzadeh and Jonathan Z. Li, Frontiers in Immunology, July 24, 2019
Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART – Nadine Bachmann et al, Nature Communications, July 19, 2019
A broad drug arsenal to attack a strenuous latent HIV reservoir – Mateusz Stoszko, Enrico Ne, Erik Abner and Tokameh Mahmoudi, Current Opinion in Virology, July 16, 2019
Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Obstacles – Tae-Wook Chun, Robert W. Eisinger and Anthony S. Fauci, JAMA, June 6, 2019
Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs – Ivan Sadowski and Farhad B. Hashemi, Cellular and Molecular Life Sciences, May 25, 2019
Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size – Daniel I. S. Rosenbloom et al, PLoS Computational Biology, April 12, 2019
DC-based immunotherapy as strategy to purge the HIV reservoir? – Ole S. Søgaard, EBioMedicine, April 10, 2019
Revisiting the ‘sterilising cure’ terminology: a call for more patient-centred perspectives on HIV cure-related research – Luke Newton et al, Journal of Virus Eradication, April 3, 2019
HIV “cure”: A shot in the arm? – Michael J. Pelusoa, Steven G. Deeks and Joseph M. McCune, EBioMedicine, April 2019
Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies – Aurélie Delannoy, Mikaël Poirier and Brendan Bell, Viruses, March 18, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting (free registration required to access) – Boris Julg et al, Lancet HIV, March 15, 2019
Transplant success reignites interest in reprogramming cells against HIV – Colin Barras, Nature Medicine, March 14, 2019
Gene Therapy Approaches to Functional Cure and Protection of Hematopoietic Potential in HIV Infection – Tetsuo Tsukamoto, Pharmaceutics, March 11, 2019
Current challenges and recent advances in the search for a cure for HIV – R. Brad Jones, Journal of the International AIDS Society, February 7, 2019
Establishment of latent HIV-1 reservoirs: what do we really know? – Jef Vanhamel, Anne Bruggemans and Zeger Debyser, Journal of Virus Eradication, January 1, 2019
Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction – Hongbing Yang, Zoë Wallace and Lucy Dorrell, Frontiers in Immunology, December 4, 2018
Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed – Jeffrey M. Jacobson and Kamel Khalili, AIDS Reviews, October-December 2018
Antibody-mediated prevention and treatment of HIV-1 infection – Henning Gruell and Florian Klein, Retrovirology, November 16, 2018
HIV control: Is getting there the same as staying there? – Philip Goulder and Steven G. Deeks, PLoS Pathogens, November 1, 2018
Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation – Lucrezia Colonna et al, Nature Communications, October 25, 2018
Ethical considerations for HIV cure-related research at the end of life – Karine Dubé et al, BMC Medical Ethics, October 20, 2018
Improved assays to measure and characterize the inducible HIV reservoir – Marta Massanella et al, EBioMedicine, October 10, 2018
Dual TLR2 and TLR7 agonists as HIV latency-reversing agents – Amanda B. Macedo et al, JCI Insight, October 4, 2018
Genetic Strategies for HIV Treatment and Prevention – Alexander Falkenhagen and Sadhna Joshi, Molecular Therapy Nucleic Acids, September 28, 2018
Long-term remission despite clonal expansion of replication-competent HIV-1 isolates – Rebecca T. Veenhuis et al, JCI Insight, September 20, 2018
No recovery of replication-competent HIV-1 from human liver macrophages – Abraham J. Kandathil et al, Journal of Clinical Investigation, September 10, 2018
The Need to Track Payment Incentives to Participate in HIV Research – Brandon Brown et al, IRB: Ethics & Human Research, July-August 2018
Perceptions of HIV cure research among people living with HIV in Australia – Jennifer Power et al, PLoS One, August 24, 2018
The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies – Golnaz Namazi et al, The Journal of Infectious Diseases, August 6, 2018
Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir – Biswajit Das et al, PNAS, July 30, 2018
Sex Differences in HIV Infection: Mystique Versus Machismo – Eileen P. Scully, Pathogens and Immunity, July 13, 2018
Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir – Pavitra Roychoudhury et al, BMC Biology, July 11, 2018
HIV Infection: Advances Toward a Cure – Daniel C. Douek, Topics in Antiviral Medicine, April 2018
Visualizing the Immune System: Providing Key Insights into HIV/SIV Infections – Jacob D. Estes, Roger LeGrand and Constantinos Petrovas, Frontiers in Immunology, March 2, 2018
Use of ‘eradication’ in HIV cure-related research: a public health debate – Karine Dubé et al, BMC Public Health, February 13, 2018
Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir – Zheng Wang, Francesco R. Simonetti, Robert F. Siliciano and Gregory M. Laird, Retrovirology, February 13, 2018
Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs – Amy E. Baxter, Una O’Doherty and Daniel E. Kaufmann, Retrovirology, February 3, 2018
HIV evolution and diversity in ART-treated patients – Gert van Zyl, Michael J. Bale and Mary F. Kearney, Retrovirology, January 30, 2018
What do we measure when we measure cell-associated HIV RNA – Alexander O. Pasternak and Ben Berkhout, Retrovirology, January 29, 2018
Single-molecule techniques to quantify and genetically characterise persistent HIV – Xiao Qian Wang and Sarah Palmer, Retrovirology, January 9, 2018
Next-generation in situ hybridization approaches to define and quantify HIV and SIV reservoirs in tissue microenvironments – Claire Deleage, Chi N. Chan, Kathleen Busman-Sahay and Jacob D. Estes, Retrovirology, January 9, 2018
Innovations in the quantitative virus outgrowth assay and its use in clinical trials – Nicholas J. Norton, Axel Fun, Mikaila Bandara, Mark R. Wills, Hoi Ping Mok and Andrew M. L. Lever, Retrovirology, December 21, 2017
Research on HIV cure: Mapping the ethics landscape – Karine Dubé et al, PLoS Medicine, December 8, 2017
Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study – Nathan W. Cummins et al, PLoS Medicine, November 28, 2017
Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption – You Jeong Park et al, Pathogens & Immunity, November 27, 2017
The mouse viral outgrowth assay: avatars for the detection of HIV-1 reservoirs – Kelly A. Metcalf Pate and Joel N. Blankson, Retrovirology, November 21, 2017
Ten Years HIV Free: An Interview with “The Berlin Patient,” Timothy Ray Brown – Michael M. Lederman and Earl Pike, Pathogens and Immunity, November 20, 2017
Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment – Gail E. Henderson1 et al, Journal of Medical Ethics, November 10, 2017
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study – Timothy J. Henrich et al, PLoS Medicine, November 7, 2017
In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a “Block-and-Lock” Strategy for HIV-1 Treatment – Cari F. Kessing et al, Cell Reports, October 17, 2017
Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum – Genevieve E Martin, José Alcami, Jean-Philippe Spano and Anna Laura Ross, Journal of Virus Eradication, October 1, 2017
The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research – Vikram Mehraj, et al, Journal of Virus Eradication, October 1, 2017
HIV cure research: print and online media reporting in Australia – Jennifer Power et al, Journal of Virus Eradication, October 1, 2017
Highlights from the 9th IAS Conference on HIV Science, 23-26 July 2017, Paris, France – Christina K Psomas, Tristan J Barber, Sofie Rutsaert and Sabine Kinloch-de Loës, Journal of Virus Eradication, October 1, 2017
Eradication of HIV-1 latent reservoirs through therapeutic vaccination – Joshua Pankrac, Katja Klein and Jamie F. S. Mann, AIDS Research and Therapy, September 12, 2017
Oral abstracts of the HIV Cure and Reservoir Symposium 2017 – Journal of Virus Eradication, September 11, 2017
Landscape review of current HIV ‘kick and kill’ cure research – Kristian Thorlund, Marc S. Horwitz, Brian T. Fife, Richard Lester and D. William Cameron, BMC Infectious Diseases, August 29, 2017
HIV-1 reservoirs in elite controllers: clues for developing a functional cure? – Megan E. May, Abena K. Kwaa and Joel N. Blankson, Future Microbiology, August 24, 2017
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal – Guoxin Wu et al, JCI Insight, August 17, 2017
Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells – Julia A. Sung et al, EBioMedicine, July 29, 2017
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency – Nancie M. Archin et al, Journal of Clinical Investigation, July 17, 2017
Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers – Elena Gonzalo-Gil, Uchenna Ikediobi, and Richard E. Sutton, Yale Journal of Biology and Medicine, June 23, 2017
Chromatin Regulation and the Histone Code in HIV Latency – Anne-Marie W. Turner and David M. Margolis, Yale Journal of Biology and Medicine, June 23, 2017
Barriers to HIV remission research in low- and middle-income countries – Theresa Rossouw, Joseph D. Tucker, Gert U. van Zyl, Kenly Sikwesi and Catherine Godfrey, Journal of the International AIDS Society, June 5, 2017
Don’t Let Funding Caps to NIH Researchers Harm Highly Collaborative HIV Cure Research – Timothy Ray Brown, AIDS Research and Human Retroviruses, June 1 2017
HIV Infection of Macrophages: Implications for Pathogenesis and Cure – Kiera L. Clayton, J. Victor Garcia, Janice E. Clements, and Bruce D. Walker, Pathogens & Immunity, May 24, 2017
Advancements in Developing Strategies for Sterilizing and Functional HIV Cures – Wei Xu et al, BioMed Research International, April 26, 2017
Cellular Senescence: A Translational Perspective – James L. Kirkland and Tamara Tchkonia, EBioMedicine, April 12, 2017
A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir – Axel Fun, Hoi Ping Mok, Mark R. Wills and Andrew M. Lever, Scientific Reports, February 24, 2017
How to Keep HIV Cure-Related Trials Ethical: The Benefit/Risk Ratio Challenge – Nir Eyal, BMJ Blogs, February 20, 2017
Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit ratio – Rahul Kumar, Journal of Medical Ethics, February 2017
The social value of candidate HIV cures: actualism versus possibilism – Regina Brown and Nicholas Greig Evans, Journal of Medical Ethics, February 2017
Must research benefit human subjects if it is to be permissible? – Daniel Wikler, Journal of Medical Ethics, February 2017
An activist’s argument that participant values should guide risk–benefit ratio calculations in HIV cure research – David Evans, Journal of Medical Ethics, February 2017
For love and money: the need to rethink benefits in HIV cure studies – Emily Largent, Journal of Medical Ethics, February 2017
Risk and radical uncertainty in HIV research – Caspar Hare, Journal of Medical Ethics, February 2017
When to start paediatric testing of the adult HIV cure research agenda? – Seema K. Shah, Journal of Medical Ethics, February 2017
How to keep high-risk studies ethical: classifying candidate solutions – Nir Eyal, Journal of Medical Ethics, February 2017
Improving on effective antiretroviral therapy: how good will a cure have to be? – Kenneth A. Freedberg and Paul E. Sax, Journal of Medical Ethics, February 2017
Why cure, why now? – Daniel R. Kuritzkes, Journal of Medical Ethics, February 2017
The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction – Nir Eyal, Journal of Medical Ethics, February 2017
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells – Malika Hale et al, Molecular Therapy, January 28, 2017
‘Well, It’s the Risk of the Unknown… Right?’: A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States – Karine Dubé et al, PLoS One, January 25, 2017
Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity – Alyssa R. Martin et al, Journal of Clinical Investigation, January 17, 2017
IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis – Rui André Saraiva Raposo et al, JCI Insight, January 12, 2017
Engineering HIV-Specific Immunity with Chimeric Antigen Receptors – Scott G. Kitchen and Jerome A. Zack, AIDS Patient Care and STDs, December 2016
Disruption or Excision of Provirus as an Approach to HIV Cure – Keith R. Jerome, AIDS Patient Care and STDs, December 2016
Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population – Geoff Symonds, Jeffrey S. Bartlett, Hans-Peter Kiem, Marlene Tsie and Louis Breton, AIDS Patient Care and STDs, December 2016
Clinical Applications of Genome Editing to HIV Cure – Cathy X. Wang and Paula M. Cannon, AIDS Patient Care and STDs, December 2016
Combining Cell and Gene Therapy in an Effort to Eradicate HIV – Thor A. Wagner, AIDS Patient Care and STDs, December 2016
Gene Therapy to Cure HIV: Where to from Here? – Rowena Johnston, AIDS Patient Care and STDs, December 2016
A Cure for AIDS – Jeffrey Laurence, AIDS Patient Care and STDs, December 2016
HIV-1 latent reservoir: size matters – Flavia Hodel, Marion Patxot, Tiia Snäkä & Angela Ciuffi, Future Virology, November 28, 2016
Targeting the Brain Reservoirs: Toward an HIV Cure – Céline Marban et al, Frontiers in Immunology, September 30, 2016
Stem cell transplantation in strategies for curing HIV/AIDS – Gero Hütter, AIDS Research and Therapy, September 13, 2016
Broad activation of latent HIV-1 in vivo – Kirston Barton et al, Nature Communications, September 8, 2016
Cancer therapies in HIV cure research – Thomas A. Rasmussen, Jenny L. Anderson, Fiona Wightman and Sharon R.Lewin, Current Opinion in HIV & AIDS, September 7, 2016
Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change – Giuseppe Pantaleo and Yves Levy, Current Opinion in HIV & AIDS, September 7, 2016
International AIDS Society: Global Scientific Strategy Towards an HIV Cure 2016 – Steven G. Deeks et al, Nature Medicine, July 11, 2016
Defining HIV and SIV Reservoirs in Lymphoid Tissues – Claire Deleage et al, Pathogens & Immunity, June 2016
CRISPR/Cas9: a double-edged sword when used to combat HIV infection – Chen Liang, Mark A. Wainberg, Atze T. Das and Ben Berkhout, Retrovirology, May 27, 2016
Targeting the latent reservoir to achieve functional HIV cure – Daniele C. Cary and B. Matija Peterlin, F1000Research, May 26, 2016
HIV-1 Reservoirs During Suppressive Therapy – Kirston Barton, Anni Winckelmann and Sarah Palmer, Trends in Microbiology, May 2016
Synergies, tensions and challenges in HIV prevention, treatment and cure research: exploratory conversations with HIV experts in South Africa – Keymanthri Moodley, Theresa Rossouw, Ciara Staunton, and Christopher J. Colvin, BMC Medical Ethics, April 30, 2016
Novel gene and cellular therapy approaches for treating HIV – Vijay G. Bhoj, Suzanne R. Thibodeaux and Bruce L. Levine, Discovery Medicine, April 28, 2016
Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV – Alison Hill et al, PLoS Pathogens, April 27, 2016
HIV overcomes CRISPR gene-editing attack – Ewen Callaway, Nature News, April 7, 2016
Perspectives for immunotherapy: which applications might achieve an HIV functional cure? – Vincent Vieillard et al, Oncotarget, February 29, 2016
Barriers to a cure for HIV in women – Sara Gianella, Athe Tsibris, Liz Barr and Catherine Godfrey, Journal of the International AIDS Society, February 18, 2016
Curing HIV: Moving Forward Faster – Marcella Flores and Rowena Johnston, AIDS Research and Human Retroviruses, February 2016
Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research – Paul W. Denton, Ole S. Søgaard and Martin Tolstrup, Journal of Translational Medicine, February 9, 2016
Broadly Neutralizing Antibodies for HIV Eradication– Kathryn E. Stephenson and Dan H. Barouch, Current HIV/AIDS Reports, February 3, 2016
Women in HIV cure research: multilevel interventions to improve sex equity in recruitment– Mary E Grewe et al, Journal of Virus Eradication, February 2016
Perspectives of Genome-Editing Technologies for HIV Therapy – Hirotaka Ebina, Peter Gee and Yoshio Koyanagi, Current HIV Research, January 2016
HIV reservoirs: what, where and how to target them – Melissa J. Churchill, Steven G. Deeks, David M. Margolis, Robert F. Siliciano & Ronald Swanstrom, Nature Reviews Microbiology, November 30, 2015 (free registration required)
Aviremia 10 Years Postdiscontinuation of ART Initiated During Primary HIV Infection – Sabine Kinloch-de Loes et al, Open Forum Infectious Diseases, Fall 2015
Challenges and opportunities for T-cell-mediated strategies to eliminate HIV reservoirs – Mark A. Brockman, R. Brad Jones and Zabrina L. Brumme, Frontiers in Immunology, October 2, 2015
Controlling HIV-1: non-coding RNA gene therapy approaches to a functional cure – Chantelle L. Ahlenstiel et al, Frontiers in Immunology, September 16, 2015
Specialists highlight recent advances, obstacles in HIV functional cure (also see video interviews) – Infectious Disease News, September 2015
¿Es posible curar la infección por VIH? (in Spanish) – Carolina Gutiérrez, Nadia P. Madrid and Santiago Moreno, Revista Española de Quimioterapia, Septiembre 2015
Designing and interpreting limiting dilution assays: general principles and applications to the latent reservoir for HIV-1 – Daniel I. S. Rosenbloom et al, Open Forum Infectious Diseases, August 26, 2015
How Much HIV is Alive? The Challenge of Measuring Replication Competent HIV for HIV Cure Research – Jintanat Ananworanich and John W. Mellors, EBioMedicine, July 31, 2015
Bone Marrow Gene Therapy for HIV/AIDS – Elena Herrera-Carrillo and Ben Berkhout, Viruses, July 17, 2015
A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals – Francesco Andrea Procopio et al, EBioMedicine, June 30, 2015
Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy – M. Martínez-Bonet et al, Clinical Infectious Diseases, June 10, 2015
Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells? – Wen Shi Lee, Matthew Sidney Parsons, Stephen John Kent and Marit Lichtfuss, Frontiers In Immunology, May 27, 2015
The remarkable stability of the latent reservoir for HIV-1 in resting memory CD4+ T cells – Janet M. Siliciano and Robert F. Siliciano, Journal of Infectious Diseases, April 15, 2015
Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies – A.M. Crooks et al, Journal of Infectious Diseases, April 15, 2015
Towards an HIV-1 cure: measuring the latent reservoir – Katherine M. Bruner, Nina N. Hosmane, Robert F. Siliciano, Trends in Microbiology, April 2015
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations – Gregory M. Laird, C. Korin Bullen, et al. Journal of Clinical Investigation, March 30, 2015
Very early combination antiretroviral therapy in infants: prospects for cure – Kaitlin Rainwater-Lovett, Katherine Luzuriaga, Deborah Persaud, Current Opinion in HIV & AIDS, January 2015
A cure for HIV: what will it take? – Jintanat Ananworanich and John Mellors, Current Opinion in HIV & AIDS, January 2015
HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? – Paul E. Sax et al, PLoS One, November 14, 2014
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy – Julian H. Elliott et al, PLoS Pathogens, November 13, 2014
Regenerating blood: towards engineering HIV-1-resistant hematopoietic stem cells – Gero Hütter, Regenerative Medicine, November, 2014
Framing Expectations in Early HIV Cure Research – Karine Dubé, Gail E. Henderson, David M. Margolis, Trends in Microbiology, October 2014
Latest HIV Purge Claims Prompt Calls for More Caution – Andy Coghlan and Jessica Hamzelou, New Scientist, July 22, 2014
An HIV Cure: Feasibility, Discovery, and Implementation – Anthony S. Fauci, Hilary D. Marston, Gregory K. Folkers, JAMA, July 19, 2014
Towards a Cure for HIV—Are We Making Progress? (free registration required) – Sharon R. Lewin, Steven G. Deeks, Françoise Barré-Sinoussi, Lancet, July 19, 2014
Sharon Lewin: Guiding Us Towards a Cure for HIV – Selina Lo, Lancet, July 19, 2014
Immunologic strategies for HIV-1 remission and eradication – Dan Barouch and Steven Deeks, Science, July 11, 2014
Cure of HIV-Infected Leukemia Patients with Cord Blood Transplantation – Lawrence D. Petz, Journal of Leukemia, July 10, 2014
Gene Researchers Work to Engineer HIV-Resistant Cells – Tracy Hampton, JAMA, July 09, 2014
Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1 – Janet D. Siliciano and Robert F. Siliciano, The Journal of Allergy and Clinical Immunology, July 2014
Therapeutic HIV vaccines: Prior setbacks, current advances, and future prospects – Kevin Fisher, Yegor Voronin and Richard Jefferys, Vaccine, June 23, 2014
Research into a functional cure for HIV in neonates: the need for ethical foresight (free with registration) – Seema K. Shah et al., Lancet Infectious Diseases, June 4, 2014
Developments in HIV-1 immunotherapy and therapeutic vaccination – Peter Lawrence Smith, Helen Tanner and Angus Dalgleish, F1000Prime Reports, June 2, 2014
The Sooner, the Better: More Evidence that Early Antiretroviral Therapy Lowers Viral Reservoirs in HIV-Infected Infants – Jonathan Z. Li and Rajesh T. Gandhi, Journal of Infectious Diseases, May 21, 2014
Reduced HIV Reservoirs After Early Treatment: HIV-1 Proviral Reservoirs Decay Continously Under Sustained Virologic Control in Early-Treated HIV-1- Infected Children – Katherine Luzuriaga et al, Journal of Infectious Diseases, May 21, 2014
Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? – A. Saez-Cirion, B. Jacquelin, F. Barré-Sinoussi, M. Müller-Trutwin, Philosophical Transactions of the Royal Society B: Biological Sciences, May 12, 2014
HIV Cure Research: Advances and Prospects – Caroline P. Passaes and Asier Sáez-Cirión, Virology, April 2014
HIV-1 Latency: An Update of Molecular Mechanisms and Therapeutic Strategies – Angela Battistini and Marco Sgarbanti, Viruses, April 14, 2014
Gene Therapy Targeting HIV Entry – Chuka Didigu and Robert Doms, Viruses, March 21, 2014
Practical Considerations in Gene Therapy for HIV Cure – Rodica Stan and John A. Zaia, Current HIV/AIDS Reports, January 22, 2014
HIV Cure: The Target is Clearer but Not Yet Close – Paul Volberding, MD, Annals of Internal Medicine via Project Inform, January 14, 2014
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients – Celsa A. Spina et al., PLoS Pathogens, December 26, 2013
Stem-Cell-Based Gene Therapy for HIV Infection – Anjie Zhenemail and Scott Kitchen, Viruses, December 24, 2013
Transplantation in HIV-infected subjects: is cure possible? – John A. Zaia and Stephen J. Forman, Hematology, December 6, 2013
Where Will Obama Find $100 Million for the New HIV Cure Initiative? – Jon Cohen, Science Insider, December 3, 2013
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS – Patrick Younan, John Kowalski and Hans-Peter Kiem, Viruses, November 28, 2013
Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice – David L. DiGiusto, Rodica Stan, Amrita Krishnan, Haitang Li, John J. Rossi and John A. Zaia, Viruses, November 22, 2013
Newer Gene Editing Technologies toward HIV Gene Therapy – N. Manjunath, Guohua Yi, Ying Dang and Premlata Shankar, Viruses, November 14, 2013
Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium – Damian FJ Purcell, Julian H Elliott, Anna-Laura Ross and John Frater, Retrovirology, November 13, 2013
Perspective: Immune Activation, HIV Persistence, and the Cure – Daniel Douek, IAS–USA Topics in Antiviral Medicine, September/October 2013
Stem-cell transplants may purge HIV – Erika Check Hayden, Nature News, July 3, 2013
HIV-1 transcription and latency: an update – Carine Van Lint, Sophie Bouchat and Alessandro Marcello, Retrovirology, June 26, 2013
Lessons to be learned from natural control of HIV – future directions, therapeutic, and preventive implications – David Shasha and Bruce D. Walker, Frontiers In Immunology, June 25, 2013
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs – Christine Katlama et al, The Lancet, June 15, 2013
Combined approaches for HIV cure – David Margolis and Daria Hazuda, Current Opinion in HIV/AIDS, May 2013
Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay – Gregory M. Laird et al, PLoS Pathogens, May 2013
Challenges in Detecting HIV Persistence during Potentially Curative Interventions – Steven Yukl et al, PLoS Pathogens, May 2013
HIV Cure: Knocking on the Door – Christine Durand and Charles Flexner, Clinical Pharmacology & Therapeutics, April 2013
Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials – Thomas A. Rasmussen, Martin Tolstrup, Anni Winckelmann, Lars Østergaard and Ole S. Søgaard, Human Vaccines & Immunotherapeutics, April 2013
Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study – Asier Sáez-Cirión et al, PLoS Pathogens, March 2013
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies – Susanne Eriksson et al, PLoS Pathogens, February 2013
Prospects for Treatment of Latent HIV – Kirston Barton, Brandon Burch, Natalia Soriano-Sarabia and David Margolis, Clinical Pharmacology & Therapeutics, January 2013
Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation – Thomas A. Rasmussen et al, Human Vaccines & Immunotherapeutics, January 2013
Fighting HIV with stem cell therapy: one step closer to human trials? – Joseph S Anderson and Gerhard Bauer, Expert Review of Anti-infective Therapy, October 2012
Novel Cell and Gene Therapies for HIV – James Hoxie and Carl June, Cold Spring Harbor Perspectives in Medicine, October 1, 2012
Novel Approaches To Curing HIV – Hiroyu Hatano, Infectious Disease Special Edition, September 28, 2012
Cure Research: Marching on—but over uneven terrain – Andreas von Bubnoff, IAVI Report, September 13, 2012
Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1? – Guido Vanham and Ellen Van Gulck, Retrovirology, September 7, 2012
Viral latency and potential eradication of HIV-1 – Kenneth Matreyek, Ilker Oztop, Eric Freed and Alan Engelman, Expert Review of Anti-infective Therapy, August 2012
Dormant HIV gets rude awakening – Cassandra Willyard, Nature News, July 27, 2012
Scientists Investigate Routing Latent HIV From Its Reservoirs to Achieve a Cure – M. J. Friedrich, JAMA, July 25, 2012
“Elite Controllers” Provide Clues to Keeping HIV Infection in Check – Tracy Hampton, JAMA, July 25, 2012
Evidence That Man Cured of HIV Harbors Viral Remnants Triggers Confusion – Jon Cohen, Science, June 11, 2012
HIV latency: the major hurdle in HIV eradication – Molecular Medicine, June 8, 2012
Therapeutic vaccines against HIV infection – Felipe García et al, Human Vaccines & Immunotherapeutics, May 1, 2012
Controversies in HIV cure research – Journal of the International AIDS Society, March 16, 2012
Conference highlights, 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin – AIDS Research and Therapy, March 12, 2012
Achieving a cure for HIV infection: do we have reasons to be optimistic? – Journal of Antimicrobial Chemotherapy, January 31, 2012
HIV Reservoirs and the Possibility of a Cure for HIV Infection – Journal of Internal Medicine, December 2011
HDAC Inhibitors in HIV – Immunology and Cell Biology, published online November 2011
HIV Latency – Cold Spring Harbor Perspectives, September 2011
Big Bolus for HIV/AIDS Cure Research – Jon Cohen, Science Insider, July 11, 2011
The search for a cure for persistent HIV reservoirs – AIDS Reviews, April-June 2011
HIV cure and eradication: how will we get from the laboratory to effective clinical trials? – AIDS, April 24, 2011 (full text courtesy of NATAP)
Eradication therapies for HIV infection: time to begin again – AIDS Research and Human Retroviruses, Febuary 2011
Finding a Cure for HIV: Will It Ever Be Achievable? – Journal of the International AIDS Society 2011, 14:4, January 2011
Workshop Report and Abstracts – Towards a Cure: HIV Reservoirs and Strategies to Control Them – Journal of the International AIDS Society 2010, 13(Suppl 3):I1, November 2010
What Do We Need to Do to Cure HIV Infection? – Topics in HIV Medicine, Aug/Sept 2010
HIV Cure: Controversy, Consensus, and a Consortium – AIDS Research and Human Retroviruses, 26(9): 943-946, September 2010
The Challenge of Finding a Cure for HIV Infection – Douglas D. Richman, David M. Margolis, Martin Delaney, Warner C. Greene, Daria Hazuda, Roger J. Pomerantz, Science, March 2009